Company Encyclopedia
View More
name
LUYAN PHARMA
002788.SZ
Luyan Pharma Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China. The company distributes medicines, Chinese herbal medicines, medical devices, and others; and provides medical care, elderly care, and wellness services. It also operates pharmaceutical retail chains. The company was formerly known as Luyan (Fujian) Pharma Co.
406.01 B
002788.SZMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking17/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE9.76%B
    • Profit Margin1.47%C
    • Gross Margin6.70%E
  • Growth ScoreC
    • Revenue YoY2.09%C
    • Net Profit YoY-14.19%D
    • Total Assets YoY5.20%B
    • Net Assets YoY5.24%B
  • Cash ScoreB
    • Cash Flow Margin6790.62%A
    • OCF YoY2.09%C
  • Operating ScoreA
    • Turnover1.64A
  • Debt ScoreE
    • Gearing Ratio74.98%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LUYAN PHARMA: The controlling shareholder has released the pledge on 22.5238 million shares

    LUYAN PHARMA announced that recently the company's controlling shareholder, Medicon, has completed the release of part of the shares it holds. The number of shares released from pledge is 22.5238 million shares, accounting for 16.32% of its held shares and 5.80% of the company's total share capital. The start date was November 2, 2020, and the release date is October 31, 2025. The pledgee is the Xiamen Heshan Branch of Industrial and Commercial Bank of China. As of the announcement date, Medicon and its concerted parties have pledged a total of 0 shares of the company

    Zhitong·
    SZ
    002788
    +6.98%
    Zhitong·
    SZ
    002788
    +6.98%

    LUYAN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 220 million yuan, a year-on-year decrease of 14.64%

    According to the Zhitong Finance APP, LUYAN PHARMA released its third quarter report for 2025. In the first three quarters, the company achieved operating revenue of 15.855 billion yuan, a year-on-year increase of 2.87%. The net profit attributable to shareholders of the listed company was 220 million yuan, a year-on-year decrease of 14.64%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 220 million yuan, a year-on-year decrease of 15.14%

    Zhitong·
    SZ
    002788
    +6.98%
    Zhitong·
    SZ
    002788
    +6.98%

    LUYAN PHARMA's subsidiary plans to establish 2 wholly-owned subsidiaries responsible for hotel operation management

    LUYAN PHARMA's subsidiary, LUYAN JIAWEN, plans to invest approximately 600 million RMB to establish two wholly-owned hotel management companies, aiming to create an ecosystem for medical rehabilitation and health maintenance industries. The new hotels will introduce the internationally renowned brand Hilton and its management team to handle daily operations. The registered capital of the two hotel management companies is 10 million yuan and 20 million yuan, respectively, with LUYAN JIAWEN holding a 100% stake in both

    Zhitong·
    SZ
    002788
    +6.98%
    Zhitong·
    SZ
    002788
    +6.98%

    LUYAN PHARMA released its performance for the first half of the year, with a net profit attributable to the parent company of 155 million yuan, a decrease of 18.83%

    According to the Zhitong Finance APP, LUYAN PHARMA released its semi-annual report for 2025, showing an operating income of 10.4 billion yuan, a year-on-year increase of 0.91%. The net profit attributable to shareholders of the listed company was 155 million yuan, a year-on-year decrease of 18.83%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 153 million yuan, a year-on-year decrease of 17.93%. The basic earnings per share were 0.4 yuan

    Zhitong·
    SZ
    002788
    +6.98%
    Zhitong·
    SZ
    002788
    +6.98%

    LUYAN PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 71.3236 million yuan, a decrease of 14.86%

    LUYAN PHARMA released its Q1 2025 performance report, with operating revenue of 5.174 billion yuan, a year-on-year increase of 0.74%. The net profit attributable to the parent company was 71.3236 million yuan, a year-on-year decrease of 14.86%; the net profit after deducting non-recurring gains and losses was 70.8861 million yuan, a year-on-year decrease of 14.33%. The basic earnings per share were 0.18 yuan

    Zhitong·
    SZ
    002788
    +6.98%
    Zhitong·
    SZ
    002788
    +6.98%
    © 2025 Longbridge｜Disclaimer